Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 24, 2007

Quark Pharmaceuticals Inks a Deal to Advance Preclinical Pipeline of Hearing Loss Compounds

  • Quark Pharmaceuticals and the University of Michigan Kresge Hearing Research Institute report that they will together conduct preclinical studies related to the treatment of acute hearing loss.

    The collaborators will investigate siRNA compounds that inhibit Quark’s target genes for the prevention and treatment of acoustic trauma-induced acute hearing loss.

    Quark reports that it expects to file an IND before the end of 2007 for its first hearing loss drug candidate, AHLi-11, for the prevention of cisplatin-induced ototoxic hearing loss.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »